TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00564902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3R 3'R Zeaxanthin
Description: 8 mg per day during 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lutein
Description: 9 mg of Lutein during 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein and Zeaxanthin
Description: 8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
Study: NCT03849053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mézières Therapy for Low back pain
Description: Spinal muscular global stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mézières Therapy for Low back pain
Description: Spinal muscular global stretching
Study: NCT04452357

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PLDR
Description: PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows:~Dose level 1: 56 Gy; Dose level 2: 66 Gy Drug: Gemcitabine
Study: NCT03244709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Intravenous Tocilizumab followed by subcutaneousTocilizumab
Study: NCT03332199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Description: The total program, consisting of three intervention sessions, was given over a period of 3 weeks. The one face-to-face session of an-hour's duration was provided within a week of the chemotherapy cycle following recruitment. Two booster sessions of 20-30 minutes were then conducted by phone at one-week intervals after the first intervention session.
Study: NCT03742310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
Study: NCT03028415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLEX
Description: A bone graft substitute

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone Graft (ABG)
Description: Control material administered by surgical implant
Study: NCT01263418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
Study: NCT04989556

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Therapy
Description: Receive standard symptom management by palliative care team

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Receive standard symptom management by palliative care team

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Receive standard symptom management by palliative care team

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Receive provider initiated remote contact

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Receive provider initiated remote contact

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03987529

Intervention type: OTHER
Intervention: sevoflurane
Description: volatile anesthetic

Intervention type: OTHER
Intervention: propofol
Description: intravenous anesthetic
Study: NCT02015871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study: NCT04989556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT04361136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study: NCT02308163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: subcutaneous injection
Study: NCT03802630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Description: Solution for injection (intravitreal use)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2 mg
Description: Solution for injection (Intravitreal use)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
Study: NCT02565758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-085
Description: Administered as an intravenous infusion in 28-day dosing cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-085
Description: Administered as an intravenous infusion in 28-day dosing cycles.
Study: NCT02438683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: high dose, single dose, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: low dose, single dose, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose, oral administration
Study: NCT01058681

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: effect of metabolic variations on LH pulsatility
Description: Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: effect of metabolic variations on LH pulsatility
Description: Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: effect of metabolic variations on LH pulsatility
Description: Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia.
Study: NCT02485639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine Inactivated
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants received vaccine intramuscularly (IM) on Day 0.
Study: NCT00712686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 15-30 mg, once daily, 140 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Capsule, Oral, 10-20 mg, once daily, 140 weeks
Study: NCT02263196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol and povidone iodine
Description: using from Alcohol and povidone iodine for prevention of inflammation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of alcohol and betadin
Description: using from combination Alcohol and povidone iodine for prevention of inflammation
Study: NCT03645941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Group
Description: The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.
Study: NCT03052634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC 1.5 mg/kg (HER2 Positive)
Description: 15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC 2.0 mg/kg (HER2 Positive)
Description: 15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC 2.5 mg/kg (HER2 Positive)
Description: 15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Study: NCT02063360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study: NCT03052634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC 2.0 mg/kg (HER2 Low Expression)
Description: 45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Study: NCT03424616

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Suzhou Sceneray® DBS System
Description: We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suzhou Sceneray® DBS System
Description: We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.
Study: NCT03564210

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screen time permitted
Description: Cohort will not be directed to abstain from screen time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screen Time Abstain
Description: Cohort will be directed to abstain from screen time
Study: NCT02063360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: Darunavir (DRV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: Darunavir (DRV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: Ritonavir (RTV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: Ritonavir (RTV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: Etravirine (ETR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: Etravirine (ETR)
Study: NCT00569478

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: Nursing consultations and physical training
Study: NCT01057342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadimezan
Description: 1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
Study: NCT03789344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncturists apply the seven-days' electro-acupuncture treatment on the acupoints of Neiguan points and Daling points for 30min per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Subjects in psychotherapy group would be accepted 20mins- psychotherapy per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: blank control
Description: Blank control subjects would be observed only during this investigation.
Study: NCT04226001

Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: Quality of life questionnaire
Study: NCT02118402

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified maize porridge
Description: Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
Study: NCT03375203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered once daily based upon dosing group.
Study: NCT02118402

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified maize porridge
Description: Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified maize porridge
Description: Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
Study: NCT00491751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 40 or 80 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: ascorbic acid 500 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT03938558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MS-Dance
Description: The experimental group will perform 10 weeks of dance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MS-Art
Description: The other group will contribute to the production in various ways (e.g. word art, photography, painting, ...)
Study: NCT03375203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered once daily based upon dosing group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 5 mg
Description: JNJ-42847922 will be administered as 5 mg (2\*2.5 mg capsule) oral capsules once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 10 mg
Description: JNJ-42847922 will be administered as 10 mg oral capsule once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 20 mg
Description: JNJ-42847922 will be administered as 20 mg oral capsule once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem will be administered as 5 mg or 10 mg (2\*5mg capsule) oral capsule once daily based upon the local labeling information.
Study: NCT03653910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtraq
Description: Airtraq is a kind of videolaryngoscope for intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh
Description: Macintosh is a traditional laryngoscope for intubation
Study: NCT02155543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 Formulation A
Description: One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 Formulation A
Description: One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 Formulation B
Description: One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 Formulation C
Description: One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 Formulation C
Description: One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-223575 Vehicle
Description: One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-223575 Vehicle
Description: One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 Vehicle
Description: One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
Study: NCT02966665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
Study: NCT02181504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abicipar pegol
Description: Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abicipar pegol
Description: Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham procedure
Description: Sham procedure to the study eye at weeks 12 and 16.
Study: NCT01884337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study: NCT02266134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Implementation of Measurement Based Care
Description: Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Implementation of Measurement Based Care
Description: Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.
Study: NCT02181504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham procedure
Description: Sham procedure to the study eye at weeks 12 and 16.